Fig 4. Percentage overlap between baseline and DA receptor antagonist trials.

The baseline (bc) trials were concatenated with the corresponding DA receptor antagonist trials and classified in either 6 (a) or 12 (b) clusters. Overlapping between bc and DA receptor antagonists trials could be due to the limited number (six) of allowed clusters (a). Some overlapping was removed by allowing the trials to separate in 12 clusters (b). In almost all cases, the mean percentage mixing between bc and DA receptor antagonists trials in the same cluster is within a standard deviation regardless of the number of clusters used by classifier (c). A minimum of 20% overlap between bc and DA receptor antagonists suggests a possible common, invariant, part of the mathematical model that applies to both conditions. The minimum number of clusters that produce a consistent separation of trials may indicate the required number of parameters in a mathematical model that capture trials’ details.